Summary

In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques, have led to the identification of a number of synthetically lethal gene pairs.

Market Analysis and Insights: Global Synthetic Lethality-based Drugs and Targets Market
The global Synthetic Lethality-based Drugs and Targets market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Synthetic Lethality-based Drugs and Targets market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Synthetic Lethality-based Drugs and Targets market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Synthetic Lethality-based Drugs and Targets market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Synthetic Lethality-based Drugs and Targets market.

Global Synthetic Lethality-based Drugs and Targets Scope and Market Size
Synthetic Lethality-based Drugs and Targets market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Synthetic Lethality-based Drugs and Targets market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Monotherapy
Combination Therapy

Segment by Application
Medical Research Institution
Hospital and Clinic
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
AstraZeneca
BeiGene
Clovis Oncology
GlaxoSmithKline
Pfizer
AtlasMedx
Chordia Therapeutics
IDEAYA Biosciences
Mission Therapeutics
Repare Therapeutics
Sierra Oncology
SyntheX Labs

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Synthetic Lethality-based Drugs and Targets Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 Market by Application
1.3.1 Global Synthetic Lethality-based Drugs and Targets Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Medical Research Institution
1.3.3 Hospital and Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Synthetic Lethality-based Drugs and Targets Market Perspective (2016-2027)
2.2 Synthetic Lethality-based Drugs and Targets Growth Trends by Regions
2.2.1 Synthetic Lethality-based Drugs and Targets Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Synthetic Lethality-based Drugs and Targets Historic Market Share by Regions (2016-2021)
2.2.3 Synthetic Lethality-based Drugs and Targets Forecasted Market Size by Regions (2022-2027)
2.3 Synthetic Lethality-based Drugs and Targets Industry Dynamic
2.3.1 Synthetic Lethality-based Drugs and Targets Market Trends
2.3.2 Synthetic Lethality-based Drugs and Targets Market Drivers
2.3.3 Synthetic Lethality-based Drugs and Targets Market Challenges
2.3.4 Synthetic Lethality-based Drugs and Targets Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Synthetic Lethality-based Drugs and Targets Players by Revenue
3.1.1 Global Top Synthetic Lethality-based Drugs and Targets Players by Revenue (2016-2021)
3.1.2 Global Synthetic Lethality-based Drugs and Targets Revenue Market Share by Players (2016-2021)
3.2 Global Synthetic Lethality-based Drugs and Targets Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Synthetic Lethality-based Drugs and Targets Revenue
3.4 Global Synthetic Lethality-based Drugs and Targets Market Concentration Ratio
3.4.1 Global Synthetic Lethality-based Drugs and Targets Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Synthetic Lethality-based Drugs and Targets Revenue in 2020
3.5 Synthetic Lethality-based Drugs and Targets Key Players Head office and Area Served
3.6 Key Players Synthetic Lethality-based Drugs and Targets Product Solution and Service
3.7 Date of Enter into Synthetic Lethality-based Drugs and Targets Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Synthetic Lethality-based Drugs and Targets Breakdown Data by Type
4.1 Global Synthetic Lethality-based Drugs and Targets Historic Market Size by Type (2016-2021)
4.2 Global Synthetic Lethality-based Drugs and Targets Forecasted Market Size by Type (2022-2027)

5 Synthetic Lethality-based Drugs and Targets Breakdown Data by Application
5.1 Global Synthetic Lethality-based Drugs and Targets Historic Market Size by Application (2016-2021)
5.2 Global Synthetic Lethality-based Drugs and Targets Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Synthetic Lethality-based Drugs and Targets Market Size (2016-2027)
6.2 North America Synthetic Lethality-based Drugs and Targets Market Size by Type
6.2.1 North America Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2021)
6.2.2 North America Synthetic Lethality-based Drugs and Targets Market Size by Type (2022-2027)
6.2.3 North America Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2027)
6.3 North America Synthetic Lethality-based Drugs and Targets Market Size by Application
6.3.1 North America Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2021)
6.3.2 North America Synthetic Lethality-based Drugs and Targets Market Size by Application (2022-2027)
6.3.3 North America Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2027)
6.4 North America Synthetic Lethality-based Drugs and Targets Market Size by Country
6.4.1 North America Synthetic Lethality-based Drugs and Targets Market Size by Country (2016-2021)
6.4.2 North America Synthetic Lethality-based Drugs and Targets Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Synthetic Lethality-based Drugs and Targets Market Size (2016-2027)
7.2 Europe Synthetic Lethality-based Drugs and Targets Market Size by Type
7.2.1 Europe Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2021)
7.2.2 Europe Synthetic Lethality-based Drugs and Targets Market Size by Type (2022-2027)
7.2.3 Europe Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2027)
7.3 Europe Synthetic Lethality-based Drugs and Targets Market Size by Application
7.3.1 Europe Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2021)
7.3.2 Europe Synthetic Lethality-based Drugs and Targets Market Size by Application (2022-2027)
7.3.3 Europe Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2027)
7.4 Europe Synthetic Lethality-based Drugs and Targets Market Size by Country
7.4.1 Europe Synthetic Lethality-based Drugs and Targets Market Size by Country (2016-2021)
7.4.2 Europe Synthetic Lethality-based Drugs and Targets Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size (2016-2027)
8.2 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Type
8.2.1 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2027)
8.3 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Application
8.3.1 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2027)
8.4 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Region
8.4.1 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Synthetic Lethality-based Drugs and Targets Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Synthetic Lethality-based Drugs and Targets Market Size (2016-2027)
9.2 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Type
9.2.1 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2021)
9.2.2 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Type (2022-2027)
9.2.3 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2027)
9.3 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Application
9.3.1 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2021)
9.3.2 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Application (2022-2027)
9.3.3 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2027)
9.4 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Country
9.4.1 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Country (2016-2021)
9.4.2 Latin America Synthetic Lethality-based Drugs and Targets Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size (2016-2027)
10.2 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Type
10.2.1 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Type (2016-2027)
10.3 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Application
10.3.1 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Application (2016-2027)
10.4 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Country
10.4.1 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Synthetic Lethality-based Drugs and Targets Introduction
11.1.4 AbbVie Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Synthetic Lethality-based Drugs and Targets Introduction
11.2.4 AstraZeneca Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.2.5 AstraZeneca Recent Development
11.3 BeiGene
11.3.1 BeiGene Company Details
11.3.2 BeiGene Business Overview
11.3.3 BeiGene Synthetic Lethality-based Drugs and Targets Introduction
11.3.4 BeiGene Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.3.5 BeiGene Recent Development
11.4 Clovis Oncology
11.4.1 Clovis Oncology Company Details
11.4.2 Clovis Oncology Business Overview
11.4.3 Clovis Oncology Synthetic Lethality-based Drugs and Targets Introduction
11.4.4 Clovis Oncology Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.4.5 Clovis Oncology Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Synthetic Lethality-based Drugs and Targets Introduction
11.5.4 GlaxoSmithKline Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Synthetic Lethality-based Drugs and Targets Introduction
11.6.4 Pfizer Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 AtlasMedx
11.7.1 AtlasMedx Company Details
11.7.2 AtlasMedx Business Overview
11.7.3 AtlasMedx Synthetic Lethality-based Drugs and Targets Introduction
11.7.4 AtlasMedx Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.7.5 AtlasMedx Recent Development
11.8 Chordia Therapeutics
11.8.1 Chordia Therapeutics Company Details
11.8.2 Chordia Therapeutics Business Overview
11.8.3 Chordia Therapeutics Synthetic Lethality-based Drugs and Targets Introduction
11.8.4 Chordia Therapeutics Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.8.5 Chordia Therapeutics Recent Development
11.9 IDEAYA Biosciences
11.9.1 IDEAYA Biosciences Company Details
11.9.2 IDEAYA Biosciences Business Overview
11.9.3 IDEAYA Biosciences Synthetic Lethality-based Drugs and Targets Introduction
11.9.4 IDEAYA Biosciences Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.9.5 IDEAYA Biosciences Recent Development
11.10 Mission Therapeutics
11.10.1 Mission Therapeutics Company Details
11.10.2 Mission Therapeutics Business Overview
11.10.3 Mission Therapeutics Synthetic Lethality-based Drugs and Targets Introduction
11.10.4 Mission Therapeutics Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.10.5 Mission Therapeutics Recent Development
11.11 Repare Therapeutics
11.11.1 Repare Therapeutics Company Details
11.11.2 Repare Therapeutics Business Overview
11.11.3 Repare Therapeutics Synthetic Lethality-based Drugs and Targets Introduction
11.11.4 Repare Therapeutics Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.11.5 Repare Therapeutics Recent Development
11.12 Sierra Oncology
11.12.1 Sierra Oncology Company Details
11.12.2 Sierra Oncology Business Overview
11.12.3 Sierra Oncology Synthetic Lethality-based Drugs and Targets Introduction
11.12.4 Sierra Oncology Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.12.5 Sierra Oncology Recent Development
11.13 SyntheX Labs
11.13.1 SyntheX Labs Company Details
11.13.2 SyntheX Labs Business Overview
11.13.3 SyntheX Labs Synthetic Lethality-based Drugs and Targets Introduction
11.13.4 SyntheX Labs Revenue in Synthetic Lethality-based Drugs and Targets Business (2016-2021)
11.13.5 SyntheX Labs Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details